The ErbB 2 Oncogene and Chemotherapy: a Mini-Review

REFERENCES

• Slebos RJ, Kibbelaar RE, Dalesio 0, et al. K-ras onco-gene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 1990 ; 323: 561–565.
   Google Scholar
• Mitsudomi T, Steinberg SM, Oie HK, et al. Ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res 1991; 51: 4999–5002.
   PubMed Web of Science ®Google Scholar
• Kern JA, Schwartz DA, Nordberg JE, Weiner DB, Greene MI, Tomey L, Robinson RA. p185 expression in human lung adenocarcinomas predicts shortened survival. Cancer Res 1990 ; 50: 5184-5187.
   Google Scholar
• Tateishi M, Ishida T, Mitsudomi T, Kaneko S, Sugimachi K. Prognostic value of c-erb B-2 protein expres-sion in human lung adenocarcinoma and squamous cell carci-noma. Eur J Cancer 1991; 27: 1372-1375.
   Google Scholar
• Niimi S, Nakagawa K, Yokota J, et al. Resistance to anti-cancer drugs in NIH3T3 cells transfected with c-myc and /or c-H-ras genes. Br J Cancer 1991; 63: 237–241.
   PubMed Web of Science ®Google Scholar
• Sklar MD. Increased resistance to cis-diamminedichloro-platinum (II) in NIH 3T3 cells transformed by ras oncogenes. Cancer Res 1988 ; 48: 793–797.
   PubMed Web of Science ®Google Scholar
• Toffoli G, Viel A, Tumiotto L, Buttazzi P, Biscontin G, Baiocchi M. Sensitivity pattern of normal and Ha-ras trans-formed NIH3T3 fibroblasts to antineoplastic drugs. Tumori 1989 ; 75: 423–428.
   PubMed Web of Science ®Google Scholar
• Oesterreich S, Weng CN, Qiu M, Hilsenbeck SG, Osborne CK, Fuqua SA. The small heat shock protein hsp27 is correlated with growth and drug resistance in human breast cancer cell lines. Cancer Res 1993; 53: 4443-4448.
   Google Scholar
• Ciocca DR, Fuqua SA, Lock-Lim S, Toft DO, Welch WJ, McGuire WL. Response of human breast cancer cells to heat shock and chemotherapeutic drugs. Cancer Res 1992; 52: 3648–3654.
   PubMed Web of Science ®Google Scholar
• Deuchars KL, Ling V. P-glycoprotein and multidrug resistance in cancer chemotherapy. Sem Oncol 1989; 16 (2): 156–65.
   PubMed Web of Science ®Google Scholar
• Foekens JA, Schmitt M, van Putten WL, et al. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 1992; 52: 6101-6105.
   Google Scholar
• Coussens L, Yang-Feng TL, Liao YC, et al. Tyrosine Kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985; 230: 1132–1139.
   PubMed Web of Science ®Google Scholar
• Shi D, He G, Cao S, Pan W, Zhang HZ, Yu D, Hung MC. Overexpression of the c-erbB-2/neu-encoded p185 pro-tein in primary lung cancer. Mol Carcinogen 1992; 5: 213–218.
   PubMed Web of Science ®Google Scholar
• Di Fiore PP, Pierce JH, Kraus MH, Segatto 0, King R, Aaronson SA. erbB-2 is a potent oncogene when overex-pressed in NIH/3T3 cells. Science 1987; 237: 178–181.
   Google Scholar
• Hudziak RM, Schlessinger J, Ullrich A. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH3T3 cells. Proc Natl Acad Sci USA 1987; 84: 7159-7163.
   Google Scholar
• King CR, Kraus MH, Aaronson SA. Amplification of a novel v-erb-B-related gene in a human mammary carcinoma. Science 1985; 229 : 974–976.
   PubMed Web of Science ®Google Scholar
• Kraus MH, Popescu NC, Amsbaugh SC, King CR. Overexpression of the EGF receptor related proto-oncogene erbB-2 in human mammary tumor cell lines by different mol-ecular mechanisms. EMBO J 1987; 6: 605–610.
   PubMed Web of Science ®Google Scholar
• van de Vijver M, van de Bersselaar R, Devilee P, Comelisse C, Peterse J, Nusse R. Amplification of the neu (c-erbB-2) oncogene in human mammary tumors is relatively fre-quent and is often accompanied by amplification of the linked c-erbA oncogene. Mol Cell Biol 1987; 7: 2019–2023.
   PubMed Web of Science ®Google Scholar
• Natali PG, Nicotra MR, Bigotti A, Venturo I, Slamon DJ, Fendly BM, Ullrich A. Expression of the p185 encoded by HER2 oncogene in normal and transformed human tis-sues. Int J Cancer 1990; 45: 457–461.
   PubMed Web of Science ®Google Scholar
• Berchuck A, Kamel A, Whitaker R, et al. Overexpression of HER-2/neu is associated with poor sur-vival in advanced epithelial ovarian cancer. Cancer Res 1990 ; 50: 4087-4091.
   Google Scholar
• Semba K, Kamata N, Toyoshima K, Yamamoto T. A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-Vepidermal growth factor-receptor gene and is ampli-fied in a human salivary gland adenocarcinoma. Proc Natl Acad Sci USA 1985 ; 82: 6497–6501.
   PubMed Web of Science ®Google Scholar
• Yokota T, Yamamoto T, Miyajima N, et al. Genetic alterations of c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue. Oncogene 1988; 2: 283–287.
   PubMed Web of Science ®Google Scholar
• Allred DC, Clark GM, Tandon AK, et al. HER-2/neu in node-negative breast cancer. Prognostic significance of over-expression influenced by presence of in situ carcinoma. J Clin Oncol 1992; 10: 599–605.
   Google Scholar
• Gusterson BA, Gelber RD, Goldhirsch A, et al. Prognostic importance of c-erbB-2 expression in breast can-cer: J Clin Oncol 1992; 10: 1049-1056.
   Google Scholar
• Muss H, Thor A, Kute T, et al. ErbB-2 (c-erbB-2: HER-2/neu) and S-phase fraction predict response to adjuvant chemotherapy in patient with node-positive breast cancer: Cancer and Acute Leukemia Group B Trial 8869. Proc ASCO 1993; 12: 72.
   Google Scholar
• Muss H, Thor A, Berry D, et al. C-erbB-2 expression and response to adjuvant therapy in women with node-posi-tive early breast cancer. N Engl J Med 1994; 330: 1260–6.
   PubMed Web of Science ®Google Scholar
• Paik S. Clinical significance of erbB-2 (ErbB 2) protein. Cancer Invest 1992; 10 (6): 575–579.
   PubMed Web of Science ®Google Scholar
• Borg A, Baldetorp B, Femo M, Killander D, Olsson H, Ryden S, Sigurdsson H. ErbB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett 1994 ; 81, 2: 137–44.
   PubMed Web of Science ®Google Scholar
• Pietras RJ, Arboleda J, Reese DM, et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hor-mone-independent growth in human breast cancer cells. Oncogene 1995; 10, 12: 2435–46.
   PubMed Web of Science ®Google Scholar
• Chun-Ming T, Kuo-Ting C, Reury-Pemg P, Tetsuya M, Mei-Hui C, Chikabumi K, Adi FG. Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with ErbB 2 gene expression but not with ras gene mutations. J Natl Cancer Inst 1993; 85: 897–901.
   PubMedGoogle Scholar
• Gazdar AF. Pathologic and clinical relevance of molecu-lar genetic changes in lung cancer. Proc Annu Meet Am Assoc Cancer Res 1992; 33: A606–7.
   Google Scholar
• Tsai CM, Chang KT, Wu LH, et al. Correlation between intrinsic chemoresistance and HER-2/neu gene expression, p53 gene mutations, and cell proliferation charac-teristics in non-small cancer cell lines. Cancer Res 1996; 56,1: 206–9.
   PubMed Web of Science ®Google Scholar
• Lai SL, Goldsten LJ, Gottesman MM, et al. MDR1 gene expression in lung cancer. J Natl Cancer Inst 1989; 81: 1144-1150.
   Google Scholar
• Drebin JA, Link VC, Stern DF, Weinberg RA, Greene MI. Down-modulation of an oncogene protein product and revision of the transformed phenotype by monoclonal anti-bodies. Cell 1985 ; 41: 695–706.
   Web of Science ®Google Scholar
• Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM, Ullrich A. Monoclonal antibody has antiprolif-erative effect in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 1989; 9: 1165–1172.
   PubMed Web of Science ®Google Scholar
• Hancock MC, Langton BC, Chan T, Toy P, Monathan JJ, Mischak RP, Shawver LK. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell. Cancer Res 1991; 51: 4575-4580.
   Google Scholar
• Pietras RJ, Scates S, Howell SB, Slamon DJ. Monoclonal antibody to ErbB 2 receptor modulates DNA repair and plat-inum sensitivity in human breast and ovarian carcinoma cells. Proc Annu Meet Am Assoc Cancer Res 1992 ; 33: A3272.
   Google Scholar
• Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, Slamon DJ. Antibody to Her-2/neu receptor blocks DNA repair after cisplatin in human breast and ovari-an cancer cells. Oncogene 1994; 9,7: 1829–38.
   PubMed Web of Science ®Google Scholar
• Weiner LM, Clark JI, Davey M, Li WS, Garcia de Palazzo I, Ring DB, Alpaugh RK. Phase I trial of 2B1, a bis-pecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. Cancer Res 1995; 55, 20: 4586-93.
   Google Scholar
• Weiner LM, Clark JI, Ring DB, Alpaugh RK. Clinical development of 2B1, a bispecific murine monoclonal anti-body targeting c-erbB-2 and fc gamma RIII. J Hematother 1995; 4,5: 453–6.
   PubMedGoogle Scholar
• Valone FH, Kaufman PA, Guyre PM, et al. Phase 1A/1B trial of bispecific antibody MDX 210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene Her-2/neu. J Clin Oncol 1995; 13,9: 2281–92.
   PubMed Web of Science ®Google Scholar
• Valone FH, Kaufman PA, Guyre PM, et al. Clinical tri-als of bispecific antibody MDX 210 in women with advanced breast or ovarian cancer that overexpresses Her-2/neu. J Hematother 1995; 4,5: 471–5.
   PubMedGoogle Scholar
• Weis W, Beerli R, Hellmann P, et al. EGF receptor and p 185erbB-2-specific single-chain antibody toxins differ in their cell-killing activity on tumor cells expressing both recep-tor proteins. Int J Cancer 1995; 60,1: 137–44.
   PubMed Web of Science ®Google Scholar
• Jeschke M, Wels W, Dengler W, Imber R, Stocklin E, Groner B. Targeted inhibition of tumor-cell growth by recombinant heregulin-toxin fusion proteins. Int J Cancer 1995; 60: 730–9.
   PubMed Web of Science ®Google Scholar
• Batra JK, Kasprzyk PG, Bird RE, Pastan I, King CR. Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin. Proc Natl Acad Sci USA 1992; 89,13: 5867–71.
   PubMed Web of Science ®Google Scholar
• Lupu R, Cardillo M, Harris L, Hijazi M, Rosenberg K. Interaction between erbB-receptors and heregulin in breast cancer tumor progression and drug resistance. Semin Cancer Biol 1995; 6,3: 135–45.
   PubMed Web of Science ®Google Scholar